ClinicalTrials.gg
RecruitingNCT07388680Updated Apr 22, 2026

Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia

A Phase 2/3 interventional study of Pirfenidone Capsules (400 mg) and Pirfenidone Capsules(600mg) in Radiation-induced Lung Injury and Immune-related Pneumonia, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Recruiting at 36 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
298
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Lung Injury with a site in China — 10 open to participants now, 11 under way, 1 of them phase 3. Lung Injury · China.

Planned enrollment
4th of 18
298 · median 100
Started
2026
with 2 others
Phase 2/3
Only one
of the 22
Primary completion
2026-12
later than 6 of 10 live
Registered
20th of 22
by date
Lead sponsor
2 of 22
Beijing Continent Pharmaceutical Co, Ltd.

Among the 22 studies in Lung Injury with a site in China, this one is the 4th largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 2/3, reaches primary completion later than 6 of the 10 other live ones, and was the 20th registered.

Lung Injury

114 studies on the registry are indexed under Lung Injury; 33 are open to participants now.

Browse Lung Injury studies →

Open to participants now

10 of the 22 studies in Lung Injury with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Lung Injury studies recruiting now, 12 (48%) set no upper age limit and 8 (32%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Lung Injury with a site in China, or all of them as a file.
02

Study summary

Radiation-induced lung injury (RILI) is one of the most common thoracic-radiotherapy complications, with an incidence as high as 31.4 %. Multiple studies have shown that RILI can adversely affect patient prognosis by disrupting treatment schedules. Moreover, the widespread clinical use of immune-checkpoint inhibitors (ICIs) has further increased pulmonary toxicity when radiotherapy (RT) is combined with ICIs. Checkpoint-inhibitor-related pneumonitis (CIP)-i.e., immune-mediated lung injury-may necessitate permanent discontinuation of ICIs, diminish survival benefit, and, in severe cases, directly threaten life. The diagnosis of both RILI and CIP is based on an integrated assessment of subjective symptoms and imaging findings.RILI typically occurs 1-3 months after completion of radiotherapy, whereas CIP may emerge at any point during treatment. The two entities share similar clinical presentations: fever, dry cough, chest tightness, dyspnoea, and pleuritic chest pain. Computed tomography (CT) is the most sensitive imaging modality. Pulmonary-function testing is another routinely used clinical metric; vital capacity, total lung capacity, forced expiratory volume in 1 s (FEV₁), and diffusing capacity of the lung for carbon monoxide (DLCO) may all decline, with DLCO being the most sensitive parameter. In advanced cases, arterial oxygen and carbon-dioxide tensions may also deteriorate.Currently, RILI is managed empirically with systemic corticosteroids and supportive care; however, this approach yields limited improvement in diffusing capacity or ventilatory function, and its ability to prevent radiation-induced pulmonary fibrosis (RPF) remains undefined. Corticosteroids also remain the mainstay of CIP therapy. Pirfenidone, a potent cytokine inhibitor, attenuates fibroblast activity by reducing production of transforming growth factor-β1 (TGF-β1), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF), thereby suppressing fibroblast proliferation and extracellular-matrix collagen synthesis. Pre-clinical efficacy studies have demonstrated robust anti-inflammatory, anti-oxidant, and anti-fibrotic effects in the lung.Because RILI and pneumonitis arising from combined radio-immunotherapy are often indistinguishable in clinical practice, and because both share pathogenetic features with idiopathic pulmonary fibrosis (IPF), the investigators initiated this phase II/III trial to address the unmet medical need for effective therapy. Building on prior pre-clinical and clinical data, the study aims to establish the optimal dose of pirfenidone capsules for RILI with or without concomitant CIP and to confirm efficacy and safety.Phase II (dose-finding): The study consists of a screening period (Day -28 to Day -1), a 168-day treatment-observation period (Day 1-Day 168), a safety follow-up (28 ± 7 days after the last dose), and subsequent disease-progression and survival follow-up. Ninety subjects with RILI, with or without CIP, who meet all eligibility criteria will be randomly assigned 1:1:1 to low-dose pirfenidone (400 mg TID), high-dose pirfenidone (600 mg TID), or matching placebo.Phase III (confirmatory): The dose of pirfenidone capsules for phase III will be determined jointly by the sponsor and investigators based on accumulated efficacy and safety data. The trial structure mirrors phase II: screening (Day -28 to Day -1), 168-day treatment-observation (Day 1-Day 168), safety follow-up (28 ± 7 days after the last dose), and disease-progression and survival follow-up. Eligible subjects with RILI ± CIP will be randomized 1:1 to receive either pirfenidone capsules (400 mg or 600 mg TID, taken with meals) or identical placebo. After completion of the 28-day post-treatment follow-up, all phase III participants will enter an extension phase for long-term survival assessment every 3 months (± 7 days).This trial will investigate the progression-free survival (PFS) and overall survival (OS) associated with pirfenidone capsules in patients with Grade 2 and 3 radiation-induced lung injury (RILI), with or without chemotherapy-induced pneumonitis (CIP).

03

Conditions studied

  • Radiation-induced Lung Injury
  • Immune-related Pneumonia

Keywords

  • Radiation-induced lung injury
  • Immune-related pneumonia
  • RILI
  • CIP
  • Pirfenidone
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects must meet all the following inclusion criteria to be enrolled in this study:
  • Voluntary signing of the form, and being capable of understanding and signing the informed consent form before the study.
  • Age 18 to 75 years (inclusive of 18 and 75), with no gender restrictions.
  • Malignant tumors diagnosed by pathological histology/cytology, and having received radiotherapy to the chest.
  • According to the (CTCAE) v5.0 standard, diagnosed by the investigator as clinical RILI grade 2-3 with or without CIP. For those with CIP, the investigator determines that only hormone treatment is required.
  • At the time of enrollment, 40% ≤ DLCO as a percentage of the predicted value \< 80% (mild to moderate lung diffusion function impairment).
  • The course of radiation-induced lung injury is less than 2 months.
  • If receiving radiation-induced lung injury-related treatment (including , antibiotics, etc.) at the time of enrollment, the types and doses of medication must remain stable within 2 weeks before enrollment, and the hormone medication does not exceed 4 weeks.
  • At the time of enrollment, the investigator assesses that the subjects can take oral administration of the drug.
  • score (ECOG) 0-2.
  • Expected survival period ≥ 6 months.
  • The functional level of major organs meets the following standards:

    1. Blood routine examination: (ANC) ≥ 1.5 × 109/L, count (PLT) ≥ 75 × 109/L or (Hb) ≥ 90 g/L;
    2. Biochemical examination: Total (TBIL), blood urea nitrogen (BUN), and creatinine (Cr) ≤ 1.5 value (ULN), or rate ≥ 50 mL/min; (ALT) or aspartate aminotransferase (AST) ≤ 2.0 ULN.

      • Creatinine clearance rate = [(140 - age) × weight (kg)] / [0.818 × Scr (umol/L)] (for females × 0.85)
  • For all fertile women, the serum pregnancy test within 7 days before the first administration must be negative, and fertile male and female subjects must agree to use reliable methods (hormonal or barrier method or abstinence) with their partners during the entire study period and at least 6 months after the last use of the investigational drug.

Exclusion criteria

Exclusion Criteria:

  • Subjects with grade C at the time of enrollment or with severe liver diseases such as liver failure, hepatic encephalopathy, etc.
  • Subjects who have had Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), drug eruption with eosinophilia and systemic symptoms (DRESS), or severe skin diseases in the past or currently;
  • Subjects who have other diseases that the investigator deems unsuitable for participation in this study during the screening process.
  • Subjects with active untreated or meningeal ; for subjects with treated central nervous system (CNS) metastases, if the symptoms are controlled for at least 4 weeks, they are eligible for enrollment;
  • Subjects who have a second that requires concurrent systemic cytotoxic chemotherapy, treatment or biological therapy (such as anti-cytotoxic T lymphocyte-associated protein 4 [CTLA4] or human epidermal growth factor receptor 2 [] monoclonal antibodies), but are allowed to enroll if they have a second malignancy that only requires hormone therapy (such as gonadotropin-releasing hormone [LHRH] agonists, tamoxifen, etc.);
  • Subjects with a history of (HIV) infection, or positive HIV antibodies or suspected HIV infection.
  • Subjects who cannot discontinue tetracycline antibiotics (such as doxycycline, minocycline, etc.) within 14 days before screening or during the study.
  • Subjects who the investigator deems unable to follow the testing procedures (such as being unable to tolerate the interruption of assisted oxygen supply during pulmonary function tests).
  • Subjects who have used or are to use drugs that may have preventive and/or therapeutic effects on radiation pneumonitis within 1 month before screening or during the study, such as pentoxifylline, angiotensin-converting enzyme inhibitors, berberine, ursolic acid, statins, nicorandil, stem cells, interferon-γ, penicillamine, etc.;
  • Subjects who have used nintedanib or high-dose acetylcysteine within 1 month before randomization;
  • Subjects who have used known or judged by the investigator to be beneficial to lung injury Chinese herbal medicines or other substances during the 1 month before randomization;
  • Subjects who have received or been exposed to or attenuated live vaccines or plan to receive live vaccines or attenuated live vaccines (except anti-tumor treatment live vaccines) during the study;
  • Subjects who have used drugs that are strong inhibitors or inducers of cytochrome CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1 within 1 month before screening or during the study;
  • Female subjects who are breastfeeding at the time of screening or male subjects whose partner is planning to get pregnant during the study.
  • Subjects with known mental disorders that may affect the study assessment or with poor compliance.
  • Subjects who are allergic to any active ingredients of this drug or its (such as lactose) or lactose intolerant.
  • Subjects who had severe trauma or received surgery within 1 month before screening or during the study, or who plan to undergo surgery during the study.
  • Subjects who, according to the investigator's judgment, have other serious systemic diseases or laboratory test abnormalities or other reasons that make them unsuitable for participating in this clinical trial.
  • Subjects who plan to participate in other drug clinical trials during the study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
298 participants (estimated)

Study arms

  • Experimental
    Low-dose group

    Pirfenidone Capsules (Low-dose group: 400 mg, TID)

    Drug: Pirfenidone Capsules (400 mg)

  • Experimental
    High-dose group

    Pirfenidone Capsules (High-dose group: 600 mg, TID)

    Drug: Pirfenidone Capsules(600mg)

  • Placebo comparator
    Placebo group

    Pirfenidone Capsules(0mg,TID)

    Drug: Pirfenidone Capsules(0mg)

Interventions

  • DrugPirfenidone Capsules (400 mg)

    Low-dose group:400 mg, TID

  • DrugPirfenidone Capsules(600mg)

    Pirfenidone Capsules(600mg,TID)

  • DrugPirfenidone Capsules(0mg)

    Placebo(0mg,TID)

06

What researchers measure

Primary outcomes

  1. Phase II and Phase III: The absolute value of the change in the predicted percentage of lung carbon monoxide diffusion capacity (DLCO% predicted) from the baseline at week 24.

    DLCO% is a core indicator for evaluating pulmonary gas exchange function, reflecting the efficiency of oxygen transfer from the alveoli into the bloodstream. It is crucial for the diagnosis and prognosis of interstitial lung disease, pulmonary vascular disease, and similar conditions. DLCO% = measured diffusing capacity of the lung for carbon monoxide ÷ predicted value × 100%. Absolute value change refers to the direct difference between two consecutive measurements (for example, a decrease from 65% to 55% represents an absolute value change of -10%).

    Time frame: At the 24th week of the experiment

Secondary outcomes

  1. Phase II and Phase III: The absolute values of the changes in DLCO% at weeks 2, 4, 8, and 16 compared to the baseline.

    Time frame: At weeks 2, 4, 8 and 16 of the trial

  2. Phase II and III: Compared with the baseline, the changes in the measured values of pulmonary carbon monoxide diffusion capacity (DLCO) (in units of liters [L]) at weeks 2, 4, 8, 16, and 24.

    Time frame: At weeks 2, 4, 8,16 and 24 of the trial

  3. Phase II and Phase III: Changes in forced vital capacity (FVC) (in liters) from baseline at weeks 2, 4, 8, 16, and 24.

    Time frame: At weeks 2, 4, 8,16 and 24 of the trial

  4. Phase II and Phase III: The absolute value changes of forced vital capacity as a percentage of the predicted value (FVC%) from baseline at weeks 2, 4, 8, 16, and 24.

    Time frame: At weeks 2, 4, 8,16 and 24 of the trial

  5. Phase II and Phase III: Changes in forced expiratory volume in one second (FEV1) (in liters) from baseline at weeks 2, 4, 8, 16, and 24.

    Time frame: At weeks 2, 4, 8,16 and 24 of the trial

  6. Phase II and Phase III: The absolute value of the change in forced expiratory volume in one second as a percentage of the predicted value (FEV1%) from baseline at weeks 2, 4, 8, 16, and 24.

    Time frame: At weeks 2, 4, 8,16 and 24 of the trial

  7. Phase II and Phase III: Changes in FEV1/FVC from baseline at weeks 2, 4, 8, 16, and 24.

    Time frame: At weeks 2, 4, 8,16 and 24 of the trial

  8. Phase II and Phase III: Changes in the St. George's Respiratory Questionnaire (SGRQ) scores from baseline at weeks 4, 8, 16, and 24.

    The St. George's Respiratory Questionnaire (SGRQ) score is the standard instrument for assessing health-related quality of life in patients with chronic airway diseases. It comprises 76 items grouped into three domains-symptoms, activity, and disease impact. Each domain score and the overall total score are scaled from 0 to 100: 0 denotes "complete absence of symptoms or limitation," whereas 100 indicates "maximal severity." Higher scores signify a greater adverse effect of the disease on daily life.

    Time frame: At weeks 4, 8,16 and 24 of the trial

  9. Phase II and Phase III: Changes in cough score from baseline at weeks 2, 4, 8, 16, and 24.

    The cough score is a subjective instrument that quantifies the frequency, intensity, and disruptive impact of cough on daily activities and sleep into a 0-10-point or 0-100-mm scale; zero denotes complete absence of cough, and higher values indicate increasing symptom severity.

    Time frame: At weeks 2, 4, 8,16 and 24 of the trial

  10. Phase II and Phase III: Changes in the Modified Medical Research Council Dyspnea Scale (mMRC) score at weeks 2, 4, 8, 16, and 24 compared to the baseline.

    The Modified Medical Research Council Dyspnea Scale (mMRC) is a five-level instrument that rapidly quantifies the extent to which breathlessness limits physical activity; higher grades indicate greater disability.

    Time frame: At weeks 2, 4, 8,16 and 24 of the trial

  11. Phase II and Phase III: Compared with the baseline, the changes in computed tomography (CT) imaging scores at weeks 4, 8, 16, and 24

    CT imaging score is a standardized method that converts anatomical or functional features observed on CT scans into quantifiable numerical values, used for disease diagnosis, staging, treatment response monitoring, or prognostic assessment.Referring to the HRCT scoring system, the scores were assigned by imaging experts after consensus , with higher values generally indicating more severe disease.

    Time frame: At weeks 4, 8,16 and 24 of the trial

  12. Phase II and Phase III: The proportion of subjects with CIP at baseline who discontinued immunotherapy and experienced immune reactivation during the study period.

    Time frame: Within 24 weeks

  13. Phase II and Phase III: The proportion of subjects whose lung injury grade decreased by at least one level compared to the baseline at week 24.

    According to the Common Terminology Criteria for Adverse Events, Version 5.0, pulmonary injury is graded, with higher grades indicating more severe symptoms.

    Time frame: Within 24 weeks

  14. Phase II and Phase III: The proportion of subjects achieving a lung injury level of ≤ 1 at the 24th week compared to the baseline.

    According to the Common Terminology Criteria for Adverse Events, Version 5.0, pulmonary injury is graded, with higher grades indicating more severe symptoms.

    Time frame: Within 24 weeks

  15. Phase II and Phase III: The time required for the subjects to first achieve a lung injury level of ≤ 1.

    According to the Common Terminology Criteria for Adverse Events, Version 5.0, pulmonary injury is graded, with higher grades indicating more severe symptoms.

    Time frame: Within 24 weeks

  16. Phase II and Phase III: The proportion of subjects who experienced their first acute pulmonary deterioration or died for any reason within 24 weeks of treatment.

    Acute pulmonary deterioration is defined as the unexplained worsening or new onset of cough, dyspnea, hypoxia, or pneumonia from the completion of initial treatment up to Week 24, persisting for \>4 days, with chest CT showing new or increased diffuse pulmonary infiltrates in the absence of pneumothorax or pleural effusion, and after exclusion of pneumonia, congestive heart failure, pulmonary embolism, or cancer progression. Pulmonary deterioration occurring within the first 2 weeks after initial treatment is not counted toward the endpoint, allowing full resolution of initial symptoms.

    Time frame: Within 24 weeks

  17. Phase II and Phase III: Analyze the blood drug concentration of pirfenidone capsules, evaluate the steady-state blood drug trough concentration for individual patients and each group of people at specific treatment time poin

    Time frame: on days 1, 14, 28, 56, 112, and 168 of the trial

  18. Phase II and Phase III: Analyze the blood drug concentration of pirfenidone capsules, evaluate the PopPK characteristics for individual patients and each group of people at specific treatment time poin

    Time frame: on days 1, 14, 28, 56, 112, and 168 of the trial

  19. Phase II and Phase III: Adverse events/serious adverse events (AE/SAE).

    Adverse Event (AE) refers to any untoward and unintended medical occurrence experienced by a trial participant during treatment or clinical investigation, regardless of causal relationship to the investigational product. Serious Adverse Event (SAE) is a subset of AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, causes persistent or significant disability/incapacity, leads to congenital anomaly/birth defect, or is judged medically important by the investigator. According to the Common Terminology Criteria for Adverse Events, Version 5.0, pulmonary injury is graded, with higher grades indicating more severe symptoms.

    Time frame: Within 24 weeks

  20. Phase II and Phase III:Number of participants with abnormal ECG readings

    Time frame: At weeks 2, 4, 8,16 and 24 of the trial

  21. Phase II and Phase III: vital signs( blood pressure).

    Record patient's systolic and diastolic blood pressure

    Time frame: At weeks 2, 4, 8,16 and 24 of the trial

  22. Phase II and Phase III: vital signs(pulse rate).

    Time frame: At weeks 2, 4, 8,16 and 24 of the trial

  23. Phase II and Phase III: vital signs(body temperature).

    Time frame: At weeks 2, 4, 8, 16 and 24 of the trial

  24. Phase II and Phase III: vital signs( respiratory rate data).

    Time frame: At weeks 2, 4, 8, 16 and 24 of the trial

  25. Phase II and Phase III: laboratory tests(complete blood count).

    Time frame: At weeks 2, 4, 8, 16 and 24 of the trial

  26. Phase II and Phase III: Number of participants with abnormal urinalysis

    Time frame: At weeks 2, 4, 8, 16 and 24 of the trial

  27. Phase II and Phase III: Number of participants with abnormal laboratory tests results (blood biochemistry)

    Time frame: At weeks 2, 4, 8, 16 and 24 of the trial

  28. Phase II and Phase III: Number of participants with abnormal laboratory tests results (coagulation function)

    Time frame: At weeks 2, 4, 8, 16 and 24 of the trial

  29. Phase II and Phase III: laboratory tests( pregnancy test for safety assessment).

    Time frame: At weeks 2, 4, 8, 16 and 24 of the trial

Other outcomes

  1. Phase II and Phase III : Analysis of the correlation between cytokines and efficacy and safety.

    Flow cytometry was employed to analyze the correlation between pirfenidone and immune-cell subsets (CD8⁺ T cells, CD4⁺ T cells, regulatory T cells \[Treg\], and macrophages).

    Time frame: on days 1, 28, and 168 of the trial

07

Study locations

36 of 36 sites recruiting
  • Anhui Provincial Chest Hospital
    Hefei, Anhui, China
    Recruiting
    • XuHong Min · Contact
  • Chinese Academy of Medical Sciences Cancer Hospital
    Beijing, Beijing Municipality, China
    Recruiting
    • Nan Bi · Contact
  • Affiliated Hospital of Fujian Medical University, Xiehe Branch
    Fuzhou, Fujian, China
    Recruiting
    • Benhua Xu · Contact
  • Fujian Provincial Cancer Hospital
    Fuzhou, Fujian, China
    Recruiting
    • Jiancheng Li · Contact
  • Lanzhou University First Hospital
    Lanzhou, Gansu, China
    Recruiting
    • Juntao Ran · Contact
  • Foshan First Hospital
    Foshan, Guangdong, China
    Recruiting
    • Rong Huang · Contact
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
    Recruiting
    • Yi Pan · Contact
  • Panyu Central Hospital Affiliated to Guangzhou Medical University
    Guangzhou, Guangdong, China
    Recruiting
    • Jiazhuo Hu · Contact
  • Southern Medical University - Southern Hospital
    Guangzhou, Guangdong, China
    Recruiting
    • Jian Guan · Contact
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
    Recruiting
    • Ming Chen · Contact
  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine
    Guangzhou, Guangdong, China
    Recruiting
    • Linzhuo Zhai · Contact
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
    Recruiting
    • Yong Bao · Contact
  • Gaozhou People's Hospital
    Maoming, Guangdong, China
    Recruiting
    • Zunbei Wen · Contact
  • Chinese Academy of Medical Sciences Cancer Hospital Shenzhen Branch
    Shenzhen, Guangdong, China
    Recruiting
    • Lvhua Wang · Contact
  • Shenzhen People's Hospital
    Shenzhen, Guangdong, China
    Recruiting
    • Zihuang Li · Contact
  • Affiliated Hospital of Guangdong Medical UniversityAffiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong, China
    Recruiting
    • Huailin Chen · Contact
  • Zhongshan People's Hospital
    Zhongshan, Guangdong, China
    Recruiting
    • Minying Li · Contact
  • Guangxi Medical University Cancer Hospital
    Nanning, Guangxi, China
    Recruiting
    • Long Cheng · Contact
  • The Second Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou, China
    Recruiting
    • Yuju Bo · Contact
  • Hebei University Affiliated Hospital
    Baoding, Hebei, China
    Recruiting
    • Hongyun Shi · Contact
  • Anyang City Cancer Hospital
    Anyang, Henan, China
    Recruiting
    • Anping Zheng · Contact
  • Henan Provincial Cancer Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Hong Ge · Contact
  • Hubei Provincial Cancer Hospital
    Wuhan, Hubei, China
    Recruiting
    • Guang Han · Contact
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
    • Qian Chu · Contact
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
    • Rui Meng · Contact
  • Xuzhou Medical University Affiliated Hospital
    Xuzhou, Jiangsu, China
    Recruiting
    • Xin Ding · Contact
  • Gansu Provincial Cancer Hospital
    Gansu, Lanzhou, China
    Recruiting
    • Shihong Wei · Contact
  • Jining First People's Hospital
    Jining, Shandong, China
    Recruiting
    • Leilei Yuan · Contact
  • Fudan University Cancer Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Zhengfei Zhu · Contact
  • Shanghai Chest HospitalShanghai Chest Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Wen Yu · Contact
  • Sichuan Provincial Cancer Hospital
    Chengdu, Sichuan, China
    Recruiting
    • Qifeng Wang · Contact
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
    Recruiting
    • Jianxin / Lin Xue / Zhou · Contact
  • Hunan Provincial Cancer HospitalHunan Provincial Cancer Hospital
    Changsha, Wuhan, China
    Recruiting
    • Hui Wang · Contact
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Qichun Wei · Contact
  • Zhejiang Provincial Cancer HospitalZhejiang Provincial Cancer Hospital
    Hangzhou, Zhejiang, China
    Recruiting
    • Yongling Ji · Contact
  • Taizhou Cancer Hospital
    Taizhong, Zhejiang, China
    Recruiting
    • Yujin Xu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Feb 5, 2026
StartActual
Mar 26, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07388680
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Mar 26, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Apr 22, 2026

Study contacts

Ming Chen
Contact
chenming@sysucc.org.cn
13600470913
Ming Chen
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion